IQVIA combines large-scale clinical development with healthcare data, analytics, technology and real-world evidence, giving sponsors a broader evidence-generation platform than trial execution alone.

Data-driven feasibility, site intelligence, real-world evidence and technology-supported clinical operations remain central differentiators.

Large pharma, biotech, oncology, cardiovascular/metabolic disease, immunology, neuroscience and complex multinational development.

Large, global and data-intensive programs requiring broad geographic reach and sophisticated evidence capabilities.

PPD contributes global clinical operations, Thermo Fisher adds laboratory and supply infrastructure, and Clario strengthens endpoint-data capabilities used across clinical development.

Thermo Fisher completed its acquisition of Clario on 24 March 2026, materially broadening its clinical endpoint-data platform alongside PPD and laboratory services.

Large biopharma, oncology, neuroscience, vaccines, rare disease, advanced therapies and laboratory-intensive development.

Complex programs requiring close coordination among clinical operations, laboratories, clinical supplies and endpoint technologies.

ICON operates one of the industry’s broadest multinational clinical-development platforms, strengthened materially by the PRA Health Sciences integration.

In 2026 ICON expanded its AI strategy through Microsoft and Anthropic collaborations supporting protocol digitisation, feasibility, site intelligence, monitoring and regulatory workflows within its Orbis platform.

Large biopharma, oncology, cardiovascular disease, neuroscience, immunology, rare disease and vaccines.

Large multinational Phase II–III programs and sponsors requiring full-service, FSP or hybrid outsourcing at scale.

Parexel combines multinational clinical operations with regulatory, scientific and consulting depth, particularly where development strategy and execution need to remain closely connected.

Parexel launched ParexelAI in May 2026, consolidating human-led AI services and capabilities across the clinical-development lifecycle.

Complex pharmaceuticals, biotech, oncology, neuroscience, immunology, rare disease and regulatory-intensive programs.

Global development where regulatory strategy, scientific input and clinical execution must operate together.

Medpace has a strong position among biotechnology sponsors and uses an integrated model that combines clinical operations with owned central laboratories and other core services.

Integrated delivery remains central, particularly for emerging and midsize biopharma companies that want fewer independent vendors.

Biotechnology, oncology, cardiovascular/metabolic disease, infectious disease, neuroscience, rare disease and advanced therapies.

Small and midsize biopharma seeking a single CRO to take substantial cross-functional responsibility.

Tigermed has evolved from a China-focused provider into one of the largest China-origin international clinical-development organizations.

Its 2026 interim results reported 11,984 employees across 43 countries, continued overseas growth, AI and decentralized-trial development, laboratory acquisitions and a new global headquarters in Hangzhou.

China drug development, APAC programs, biotechnology, pharmaceuticals, medical devices and international registration studies.

Sponsors for whom China is strategically important and who also need wider APAC or multinational execution.

Fortrea became independent after Labcorp’s 2023 spin-off of its clinical-development business, while retaining decades of clinical-development heritage.

In September 2026 Fortrea agreed to acquire Worldwide Clinical Trials’ Early Phase Services division, including a 200-bed clinical pharmacology unit and GLP bioanalytical laboratory. The transaction remained pending at the review date.

Pharma, biotechnology, MedTech, oncology, metabolic disease and global registration programs.

Sponsors requiring broad international Phase I–IV infrastructure with meaningful clinical-pharmacology depth.

Syneos combines clinical development with functional outsourcing and broader medical and commercial capabilities across the biopharmaceutical lifecycle.

Technology-enabled protocol, feasibility, enrollment, monitoring and operational workflows are increasingly integrated into its clinical-development model.

Pharma, biotech, oncology, neuroscience, rare disease, immunology and broad lifecycle development.

Sponsors wanting full-service clinical operations, FSP flexibility and connections to wider lifecycle functions.

Worldwide is a therapeutically focused global CRO with particular relevance to biotechnology sponsors and complex clinical-development programs.

Worldwide completed its acquisition of Catalyst Clinical Research in February 2026, adding oncology, biometrics and FSP capability. In September it agreed to sell its Early Phase Services division to Fortrea; that transaction remained pending at the review date.

Oncology, neuroscience, rare disease, cardiovascular/metabolic and other therapeutically complex programs.

Biotech sponsors seeking international capability with a more focused operating model than a mega-CRO.

Pharmaron spans discovery, preclinical development, laboratories, manufacturing and clinical development rather than fitting a narrow pure-play CRO definition.

Its strategic value is integration across the development continuum, including small molecules, biologics and advanced modalities.

Small molecules, biologics, cell and gene therapy, devices and China/US development.

Sponsors seeking continuity from discovery and nonclinical work into clinical development.

Charles River is one of the most important outsourced organizations in discovery, pharmacology, toxicology and nonclinical safety assessment.

Its 2026 activity includes AI-enabled digital pathology and participation in Lilly TuneLab to support AI/ML-enabled drug discovery using nonclinical testing expertise.

Preclinical pharmaceutical and biotechnology development, biologics, oncology and advanced modalities.

Discovery-to-IND programs and nonclinical safety development.

Eurofins supports clinical development through extensive central-laboratory, biomarker and analytical infrastructure.

Biomarker workflows, molecular assays, pathology, genomics and standardized sample management across multicountry studies.

Precision medicine, oncology, biomarkers, vaccines, cell and gene therapy and laboratory-intensive trials.

Programs where standardized biological testing and biomarker evidence are critical.

Novotech has grown from an Australia/APAC-focused CRO into an increasingly international development partner for biotechnology companies.

Connecting strong APAC infrastructure with broader global development, including expansion in Japan and other international markets.

Biotechnology, oncology, rare disease, infectious disease, advanced therapies and APAC clinical development.

Biotech companies using Australia or Asia for early development before extending to multicountry programs.

PSI is an independent global midsize CRO particularly associated with pivotal Phase II and Phase III clinical trials.

Operational consistency, recruitment performance and complex specialty development, including precision medicine and advanced therapies.

Oncology, hematology, gastroenterology, autoimmune disease, infectious disease and neuroscience.

Pivotal Phase II–III trials with demanding recruitment or operational requirements.

Precision for Medicine integrates clinical operations with biomarker, translational and precision-medicine capabilities.

McKesson announced a definitive agreement on 25 August 2026 to acquire Precision Medicine Group for approximately $2.25 billion. The transaction remained subject to regulatory clearances and closing conditions at the review date.

Oncology, rare disease, cell and gene therapy, biomarkers and advanced modalities.

Programs where biomarkers, translational science and patient stratification are integral to development.

Celerion is a specialist clinical-pharmacology organization with dedicated early-phase infrastructure and a long history of intensive human pharmacology studies.

Electronic data acquisition, real-time reporting and highly controlled early-phase execution across first-in-human and PK/PD programs.

Clinical pharmacology and early human development across pharmaceutical and biotechnology portfolios.

First-in-human, SAD/MAD, PK/PD, DDI, food-effect and other intensive early-phase studies.

CMIC is one of Japan’s longest-established and most significant outsourced clinical-development organizations.

Integrated Japanese pharmaceutical-development support, regulatory execution and regional APAC capability.

Japan market entry, domestic Japanese studies and APAC programs requiring local language and regulatory knowledge.

International sponsors requiring deep Japanese clinical and regulatory expertise.

Ergomed combines specialty clinical-development capabilities with substantial pharmacovigilance expertise through PrimeVigilance and related group businesses.

Oncology, rare disease, drug safety and technology-supported specialty clinical research.

Oncology, rare disease and programs with complex or intensive safety requirements.

Specialty programs where clinical operations and pharmacovigilance must remain tightly coordinated.

Formerly George Clinical, Emerald is a Singapore-headquartered international CRO with a strong APAC heritage.

Emerald acquired Hongyi Clinical Development Services, the independent China-based clinical CRO carved out of WuXi AppTec, creating a platform of 1,000+ professionals across 40+ countries.

Renal, oncology, cardiovascular/metabolic, autoimmune, ophthalmology and APAC development.

Sponsors seeking APAC depth combined with stronger China and multinational execution.

Cliantha is an India-headquartered CRO with integrated clinical and laboratory capabilities in India and North America.

Integrated early phase, BA/BE, patient trials, laboratory, biometrics and real-world evidence services.

Generics, biosimilars, dermatology, respiratory disease, vaccines and India-centered development.

Programs requiring Indian clinical operations together with bioanalytical and laboratory infrastructure.

Emmes has a long scientific heritage in government-sponsored, public-health and methodologically complex clinical research.

Clinical data science, statistics, technology-enabled research and scientifically complex public-health and industry programs.

Public health, infectious disease, vaccines, neuroscience, rare disease and government-sponsored research.

Scientifically complex government, academic and industry studies requiring strong methodological expertise.

NAMSA is a specialist MedTech CRO and testing organization rather than a conventional pharmaceutical CRO.

NAMSA expanded its testing infrastructure in 2026 through acquisition of selected Labcorp early-development medical-device testing assets.

Medical devices, diagnostics, IVDs and related MedTech products.

Device and diagnostics companies requiring specialist clinical, regulatory and testing expertise.

ClinChoice operates across North America, Europe and Asia-Pacific and supports both full-service and functional outsourcing.

Flexible multinational delivery for emerging and midsize sponsors, with strong connections between Western and Asian markets.

Biotechnology, pharmaceuticals and cross-border clinical development.

Sponsors looking for a midsize global CRO with meaningful Asia and Western-region capability.

QPS connects preclinical research, bioanalysis and clinical development in a single organization.

Expanded RWE capability, AI integration and additional validated analytical assays complement its translational and clinical-development platform.

Oncology, obesity/metabolic research, vaccines, dermatology, neuropsychiatry and translational medicine.

Programs where bioanalysis, PK or translational evidence need to remain closely linked to clinical development.

Rho combines full-service clinical development with a particularly strong heritage in biometrics, data standards and regulatory science.

Statistics, data quality, submission readiness and risk-based clinical execution remain key differentiators.

Data-intensive biotechnology and pharmaceutical development.

Studies where statistical, data and regulatory quality are central to development success.

Premier Research is well established in difficult therapeutic and special-population clinical development.

Complex oncology designs, biomarker-guided research, adaptive trials and rare-disease development.

Rare disease, oncology, hematology, pediatrics, neuroscience and advanced therapies.

Programs involving small, specialized or difficult-to-recruit patient populations.

CTI combines clinical-trial execution with development consulting and specialist research capabilities.

CTI launched its ConneCTIva clinical-technology platform in 2026 and expanded its research network through acquisition activity.

Biotechnology, transplantation, rare disease, nephrology and specialized clinical programs.

Sponsors wanting clinical operations combined with strategic consulting and specialty research expertise.

EPS is an established Japanese CRO platform with significant clinical-development relevance in Japan and wider Asia.

Japan/Asia clinical execution and cross-border support for regional development programs.

Japanese pharmaceutical development and Asian multinational programs.

Sponsors entering Japan or linking Japanese development with broader Asian studies.

ProPharma combines clinical services with regulatory sciences, pharmacovigilance, quality and medical information.

Integrated lifecycle support for companies that need several specialist disciplines without building separate vendor relationships for each.

Pharma, biotech, medical devices and companies needing regulatory and safety infrastructure.

Sponsors requiring regulatory, quality and safety support alongside clinical development.

Veristat is a science-focused CRO and consultancy specializing in complex development programs and important regulatory milestones.

In 2026 Veristat announced an intended acquisition of Certara’s Regulatory and Medical Writing business, which would materially increase specialist regulatory depth.

Rare disease, oncology, advanced therapies and complex biotechnology programs.

Emerging sponsors approaching important scientific and regulatory milestones.

Allucent is designed particularly around small and midsize biopharma companies rather than mega-CRO portfolio scale.

High-touch clinical-development support, patient/site engagement and flexible hybrid research models.

Oncology, neuroscience, immunology, infectious disease, rare disease and cell/gene therapy.

Emerging biopharma requiring specialist global development support.

Caidya is a specialty global CRO built through combinations including dMed and Clinipace.

Its June 2026 combination with Simbec-Orion added dedicated clinical-pharmacology capability and strengthened European oncology and rare-disease expertise.

Biotechnology, oncology, rare disease and cross-border clinical development.

Sponsors seeking continuity from early human development into multinational later-phase trials.

hVIVO is highly specialized in controlled human-infection and human-challenge research.

Human-challenge models, respiratory and infectious-disease research, supported by broader early-development capabilities.

Infectious disease, respiratory disease, vaccines and antivirals.

Programs where controlled human-infection models can answer early proof-of-concept questions.

Altasciences connects nonclinical safety, clinical pharmacology, bioanalysis, formulation and manufacturing within an early-development platform.

Moving compounds efficiently from nonclinical work into first-in-human and proof-of-concept development.

Early pharmaceutical and biotechnology development.

First-in-human, PK/PD, DDI, BA/BE and other early-development programs.

Advanced Clinical combines full-service clinical research, FSP and strategic-resourcing models.

Flexible outsourcing, hybrid/decentralized trial delivery, global feasibility and patient/site engagement.

Oncology, rare disease, dermatology and flexible sponsor-resourcing models.

Sponsors wanting to combine full-service execution with function-specific outsourcing.

MMS concentrates heavily on biometrics, clinical data, regulatory documentation and safety rather than broad site-management scale.

Data science, submission readiness, trial design and technology-supported regulatory and pharmacovigilance workflows.

Oncology, radiopharmaceuticals, CNS, rare disease and submission-intensive development.

Sponsors needing deep statistics, data, medical writing or regulatory-submission support.

LSK Global PS is one of South Korea’s established independent full-service clinical-research organizations. KoNECT reports more than 1,690 trials, including 180+ global clinical trials.

Korean clinical development with integrated statistics, data management, clinical operations, medical writing, regulatory, pharmacovigilance and quality functions.

South Korean clinical development and multinational studies involving Korea.

Sponsors for whom South Korea is a major development country and local operating depth is important.

Everest is a data-focused full-service CRO that has grown from a biometrics consultancy into a global organization with more than 750 employees and clinical operations across North America, Europe and Asia.

Full-service execution anchored by biometrics, regulatory strategy, data management and technology-enabled study delivery; a September 2026 acquisition further expanded its data-services platform.

Pharma and biotech programs requiring substantial biometrics support.

Data-intensive trials where clinical operations and biometrics must remain closely coordinated.

P95 Julius Clinical is a global, science-led CRO combining conventional clinical development with epidemiology and real-world evidence expertise.

The 2025 merger created a 500+ person organization spanning 25+ countries, and 2026 work includes an international Parkinson’s platform trial with operations across the US and Europe.

Infectious disease and vaccines, neuroscience and cardio-renal-metabolic research.

Programs where clinical trials need to connect with epidemiology, registries or RWE.

Alimentiv is a specialist CRO focused on gastrointestinal clinical research and disease-specific scientific services.

Disease-specific global GI trial delivery, centralized imaging, histopathology, biomarker and statistical innovation, supported by an extensive international site network.

Crohn’s disease, ulcerative colitis, celiac disease and other gastrointestinal disorders.

GI and IBD trials where disease-specific endpoints, imaging and investigator expertise are critical.

Nucleus Network specializes in Phase I and first-in-human research through dedicated early-development facilities in Australia, the US and the UK.

A dedicated early-phase network with approximately 350 Phase I beds across Australia, the US and the UK, supported by more than 2,500 completed Phase I studies.

Biotechnology and pharmaceutical early-phase programs.

Sponsors requiring dedicated Phase I infrastructure and experienced clinical-pharmacology execution.

Avance Clinical is an Australian-headquartered CRO focused strongly on emerging biotechnology development, with growing multi-regional execution.

In 2026 Avance expanded operationally into Singapore and Malaysia, strengthened mainland China and India capability, and continued connecting Australia/Asia with North American development.

Emerging biotech, oncology, CNS, renal/metabolic and Australia/APAC clinical development.

Biotechnology companies beginning development in Australia and expanding into Asia or other international regions.

TFS is a Swedish-founded midsize global CRO providing full-service clinical development, FSP, strategic resourcing and real-world evidence.

Approximately 600 professionals working across 40+ countries and 18 office locations support full-service clinical development and strategic resourcing, with specialist depth in oncology, ophthalmology and neuroscience.

Dermatology, internal medicine, neuroscience, oncology and ophthalmology.

Sponsors looking for midsize flexibility combined with international delivery.

Linical is a Japan-origin global full-service CRO with coverage across 30+ countries and a substantial operating base spanning North America, Europe and Asia-Pacific.

Connecting Japanese regulatory and clinical capability with North American, European and broader APAC delivery.

Japanese and Japan-linked global pharmaceutical development, oncology and neurology.

Sponsors requiring Japanese expertise within a broader international clinical program.

SGS provides clinical research within a much larger global testing, inspection and laboratory organization, with dedicated clinical pharmacology, biometrics and trial-management services.

Earlier clinical decision-making, clinical pharmacology and integrated analytical evidence generation, supported by a 110-bed Phase I unit in Antwerp and broader clinical research services.

Early development, infectious disease, respiratory, oncology, dermatology and laboratory-linked pharmaceutical research.

Programs requiring clinical pharmacology and analytical testing to operate closely together.

Aixial Group is a specialty full-service CRO backed by ALTEN Group, with more than 1,000 professionals, over 30 years of experience and a direct footprint across 10 countries on three continents.

Oncology, rare disease, cell and gene therapy, radiopharmaceuticals, RWE and flexible full-service/FSP delivery for complex clinical-development programs.

Oncology, rare disease, cell and gene therapy, radiopharmaceuticals and CNS.

Complex specialty programs where therapeutic concentration is more important than mega-CRO scale.

Biorasi is a midsize full-service CRO focused on complex biotechnology development, combining a high-touch sponsor model with a broad international site network.

Global execution for small and midsize biotech companies across five core therapeutic areas, supported by regional operations in North America, Europe and India.

Oncology, dermatology, neurology, nephrology and cell therapy.

Biotechnology companies conducting specialized or operationally challenging trials.

Biotrial is a long-established early-phase and clinical-pharmacology CRO with clinical units in France and the United States and additional operations in Canada and the UK.

Advanced clinical pharmacology, first-in-human research, intensive sampling and early-development support, backed by approximately 260 dedicated clinical beds across France and the US.

Early pharmaceutical and biotechnology development.

Sponsors needing specialist Phase I infrastructure in Europe or the United States.

DreamCIS is an established South Korean CRO supporting clinical trials, observational research and post-marketing studies within a wider Tigermed-associated network.

Korean clinical execution combined with access to broader regional capabilities through Tigermed-related infrastructure.

Oncology, cardiovascular disease, endocrine disorders, rare disease and Korean clinical development.

Korea-centered clinical programs requiring experienced local execution with wider Asian connectivity.